Chemomab Therapeutics (CMMB) Cash from Operations (2017 - 2023)
Chemomab Therapeutics (CMMB) posted Cash from Operations of 3717000.0 for Q4 2023, up 28.82% on a QoQ basis from 5222000.0 in Q3 2023, and up 34.82% year-over-year from 2756932.11 in Q4 2022.
Chemomab Therapeutics (CMMB) Cash from Operations (2017 - 2023) Analysis & Trends
Chemomab Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 3717000.0 for Q4 2023.
- Quarterly Cash from Operations rose 34.82% year-over-year to 3717000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 23611000.0 (down 15.91% YoY) and the FY2025 annual result came in at 11130000.0, up 27.66% from the prior year.
- Cash from Operations was 3717000.0 for Q4 2023 at Chemomab Therapeutics, up from 5222000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 873000.0 in Q2 2020 and bottomed at 7486000.0 in Q2 2023.
- A 5-year average of 3902750.0 and a median of 3714000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2020 — Cash from Operations jumped 77.7% — and 2021, when it slumped 542.27%.
- Chemomab Therapeutics' Cash from Operations stood at 5914000.0 in 2019, then jumped by 73.71% to 1555000.0 in 2020, then plunged by 86.11% to 2894000.0 in 2021, then tumbled by 97.06% to 5703000.0 in 2022, then jumped by 34.82% to 3717000.0 in 2023.
- Business Quant data shows CMMB's Cash from Operations at 3717000.0 in Q4 2023, 5222000.0 in Q3 2023, and 7486000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -3.72 Mn |
| Dec 31, 2023 | -3.72 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Jun 30, 2023 | -7.49 Mn |
| Jun 30, 2023 | -7.49 Mn |
| Mar 31, 2023 | -7.19 Mn |
| Mar 31, 2023 | -7.19 Mn |
| Dec 31, 2022 | -5.70 Mn |
| Dec 31, 2022 | -5.70 Mn |
| Sep 30, 2022 | -5.26 Mn |
| Sep 30, 2022 | -5.26 Mn |
| Jun 30, 2022 | -5.70 Mn |
| Jun 30, 2022 | -5.70 Mn |
| Mar 31, 2022 | -3.71 Mn |
| Mar 31, 2022 | -3.71 Mn |
| Dec 31, 2021 | -2.89 Mn |
| Dec 31, 2021 | -2.89 Mn |
| Sep 30, 2021 | -2.58 Mn |
| Sep 30, 2021 | -2.58 Mn |